Dartmouth Cancer Research Featured at National Conference

June 10, 2010
Lebanon, NH

Cancer researchers from Dartmouth-Hitchcock Norris Cotton Cancer Center in Lebanon, NH, were frequent presenters throughout the annual meeting of the American Society of Clinical Oncologists (ASCO), which concluded June 8 in Chicago.

ASCO is the world's leading professional organization representing physicians who treat people with cancer. The society's members carry out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. The annual meeting's theme for 2010, "Advancing Quality through Innovation," emphasized new ideas in both research and clinical application. The event drew more than 30,000 cancer specialists from around the world.

Researchers from Dartmouth-Hitchcock Norris Cotton Cancer Center belonged to several research teams presenting results at the ASCO annual meeting. Cancer Center members and their work included:

  • Karen Skalla, MSN, APRN, AOCN: A Dartmouth-led study describing the physical, psychosocial, psychological, spiritual, and economic challenges faced by cancer survivors;
  • Peter Kaufman, MD: Research following patient-reported outcomes in clinical trials for breast-cancer patients;
  • Marc Ernstoff, MD: An investigation of denileuklin difitox's potential as an immunosuppressant for lymphoma patients;
  • Frederick Lansigan, MD: A pilot study of sorafenib examining biomarkers in lymphoma patients;
  • James Rigas, MD: The results of double-blind studies of ALD518's effectiveness in treating anemia and lean body mass loss in patients with non-small cell lung cancer;
  • Leslie DeMars, MD: A study evaluating the safety and tolerability of intraperitoneal catumaxomab in the consolidation setting for patients with minimal residual ovarian cancer;
  • Virginia Beggs, MDc, BSN, NP: A study on the effects of optimal heart failure regimens on the time course and extent of cardiac recovery of anthracycline-based chemotherapy.  

Not presented at the ASCO annual meeting but published in conjunction with the event:

  • A Dartmouth-led study by a team including the Cancer Center's James Rigas, MD, on the use of quantitative proteomics to evaluate substrates and functional modules of the aurora and polo-like kinases;
  •  A study by a team that included Frederick Lansigan, MD, on the rate of infection and immunosuppression of denileukin difitox in in cutaneous T-cell lymphoma.

Dartmouth-Hitchcock Norris Cotton Cancer Center combines advanced cancer research at Dartmouth Medical School with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center, at Dartmouth-Hitchcock regional locations in Manchester and Keene, NH, and St. Johnsbury, VT, and at 11 partner hospitals throughout New Hampshire and Vermont. It is one of 40 centers nationwide to earn the National Cancer Institute's "Comprehensive Cancer Center" designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at

Back to News